drugset / Trial / NCT00821821

Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

NCT00821821

Phase 2 Completed 36 enrolled Shionogi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.

Timeline

Start
2009-02-28
Primary completion
2010-11-30
Completion
2010-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Edaravone Unknown 1000 mg Intravenous
Subject Edaravone Unknown 2000 mg Intravenous

Indications